Efficacy and safety of niraparib combined with anlotinib maintenance retreatment in platinum-sensitive recurrent ovarian cancer patients who previously received PARP inhibitor: An open-label, single-arm, prospective, exploratory phase II study (1265)
-
Published:2023-09
Issue:
Volume:176
Page:S168
-
ISSN:0090-8258
-
Container-title:Gynecologic Oncology
-
language:en
-
Short-container-title:Gynecologic Oncology
Author:
Jin Ying,Pan Lingya,Shan Ying,Li Yan,Gu Yu,Wang Wei
Subject
Obstetrics and Gynecology,Oncology